ArticleWorld journal of nuclear medicine2022

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?

Manoj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.